Symbol | Exchange | Currency |
|---|
Leerink Partners analyst Puneet Souda maintained a Buy rating on Repligen (NASDAQ:RGEN) Corp on Tuesday, setting a price target of $250, which is approximately 33.12% above the...
Repligen (RGEN) shares shares rise nearly5%during premarket trading after the company posted strong first-quarter results, driven by COVID-19 related demand and acquisition...
Repligen (RGEN): Q1 Non-GAAP EPS of $0.68; GAAP EPS of $0.52 beats by $0.25.Revenue of $142.8M (+87.7% Y/Y) beats by $25.78M.Organic Revenue growth of 69%.FISCAL YEAR 2021...
Gilead Sciences (NASDAQ:GILD), Inc. GILD announced that the FDA has approved a label expansion of its hepatitis C virus (HCV) drug, Epclusa.The drug has now been approved for...
Commercial-stage biopharmaceutical Omeros (NASDAQ:OMER) Corporation OMER announced encouraging preliminary results from an early-stage study of its MASP-3 inhibitor, OMS906.The...
Omeros (NASDAQ:OMER) Corporation OMER announced encouraging preliminary results from the second cohort of critically ill COVID-19 patients treated with lead candidate,...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Buy |
| Technical Indicators | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
| Summary | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 2,430.20 | 2,441.72 | 2,418.96 | -4.93 | -0.20% | 1.10M | NASDAQ | |||
| 331.26 | 332.83 | 328.93 | -1.20 | -0.36% | 13.59M | NASDAQ | |||
| 6.76 | 6.85 | 6.58 | -0.04 | -0.59% | 397.81K | NASDAQ | |||
| 7.73 | 8.09 | 6.83 | +0.88 | +12.85% | 10.53M | NASDAQ | |||
| 57.33 | 57.55 | 57.01 | -0.01 | -0.02% | 12.93M | NYSE | |||
| 14.18 | 14.33 | 13.57 | +0.29 | +2.09% | 56.13M | NYSE | |||
| 5.43 | 5.50 | 5.39 | -0.01 | -0.18% | 20.37M | NYSE | |||
| 17.47 | 17.62 | 17.37 | +0.01 | +0.06% | 2.93M | NYSE | |||
| 3.84 | 3.97 | 3.72 | 0.000 | 0.00% | 9.91M | NYSE | |||
| 14.54 | 15.18 | 14.47 | -0.44 | -2.94% | 8.10M | NASDAQ | |||
| 29.23 | 31.02 | 28.65 | -1.84 | -5.92% | 18.84M | NYSE | |||
| 10.32 | 10.34 | 10.28 | +0.08 | +0.78% | 2.47M | NYSE | |||
| 28.56 | 28.75 | 25.62 | +2.84 | +11.04% | 12.78M | NASDAQ | |||
| 2.72 | 2.72 | 2.68 | +0.03 | +1.12% | 3.27M | NYSE | |||
| 9.54 | 9.93 | 9.33 | -0.19 | -1.95% | 22.58M | NYSE |
Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company's portfolio includes protein products, chromatography products, and filtration products. It provides Protein A ligands, a component of Protein A chromatography resins (media) used in the purification of virtually all monoclonal antibody (mAb)-based drugs on the market or in development. Its chromatography portfolio includes various products used in the downstream purification and quality control of biological drugs. Its OPUS pre-packed chromatography columns (PPCs) are used in the purification of clinical-stage biologics. Its filtration products include XCell Alternating Tangential Flow (ATF) Systems and Sius tangential flow filtration (TFF) cassettes. Sius TFF cassettes are used to concentrate clinical and commercial-stage biologic drugs.
